Achillion Pharmaceuticals Inc. shares are currently trading down about 1.9% on the day.

FORBES: Get An Even Better Deal On ACHN Than Director Liotta Did

Investors are still waiting to see whether hepatitis C developers Idenix Pharmaceuticals (IDIX) and Achillion Pharmaceuticals (ACHN) are taken out following similar deals for Pharmasset and Inhibitex .

FORBES: For Biotech, 'Fail' is Making a Big Comeback

Back on June 12, Achillion Pharmaceuticals Inc.

FORBES: Get An Even Better Deal On ACHN Than Director Liotta Did

Achillion Pharmaceuticals (ACHN) is waking up.

FORBES: Five Stocks For Riding This Market Rally